These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33480616)

  • 1. No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.
    Wu N; Liu L; Ren D; Yuan F; Bi Y; Guo Z; Hou B; Ji L; Han K; Feng M; Su K; Yu T; Li X; Yang F; Sun X; Dong Z; Yu S; Yi Z; Xu Y; He L; Wu S; Zhao L; Changqun C; Shi Y; He G
    Clin Neuropharmacol; 2021 Mar-Apr 01; 44(2):53-56. PubMed ID: 33480616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
    Zhang N; Ji L; Chen Z; An L; Ren D; Bi Y; Guo Z; Yuan R; Yuan F; Dong Z; Yin L; Sun X; Yang F; Li X; Yu T; He L; Shi L; He G
    Psychiatr Genet; 2020 Feb; 30(1):30-33. PubMed ID: 31842058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
    Yeh YW; Chen CJ; Jang FL; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Shyu JF; Wan FJ; Lu RB; Huang SY
    J Psychiatr Res; 2015 Feb; 61():33-9. PubMed ID: 25512257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
    Zhu Y; Zhang N; Ren D; Bi Y; Xu F; Niu W; Sun Q; Guo Z; Yuan R; Yuan F; Wu X; Cao Y; Yang F; Wang L; Du L; Li W; Xu Y; Li X; Zhu L; He L; Shi L; He G; Yu T
    Clin Neuropharmacol; 2019; 42(2):32-36. PubMed ID: 30875344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
    Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
    Marshe VS; Maciukiewicz M; Rej S; Tiwari AK; Sibille E; Blumberger DM; Karp JF; Lenze EJ; Reynolds CF; Kennedy JL; Mulsant BH; Müller DJ
    Am J Psychiatry; 2017 May; 174(5):468-475. PubMed ID: 28068779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare variants in SLC6A4 cause susceptibility to major depressive disorder with suicidal ideation in Han Chinese adolescents and young adults.
    Ran L; Ai M; Wang W; Chen J; Wu T; Liu W; Jin J; Wang S; Kuang L
    Gene; 2020 Feb; 726():144147. PubMed ID: 31629822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
    Yuan F; Yuan R; Ren D; Bi Y; Niu W; Guo Z; Wu X; Xu F; Sun Q; Ma G; Yang F; Zhu Y; Yu T; Li X; He L; Shi L; He G
    Psychiatry Res; 2020 Feb; 284():112690. PubMed ID: 31757642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
    Singh AB; Bousman CA; Ng CH; Byron K; Berk M
    Transl Psychiatry; 2012 Nov; 2(11):e198. PubMed ID: 23188198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
    Lee SH; Choi TK; Lee E; Seok JH; Lee SH; Lee HS; Kim SJ
    Neuropsychobiology; 2010 Aug; 62(3):198-206. PubMed ID: 20664233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.
    Sun Q; Yuan F; Yuan R; Ren D; Zhu Y; Bi Y; Hu J; Guo Z; Xu F; Niu W; Ma G; Wu X; Yang F; Wang L; Li X; Yu T; He L; He G
    Medicine (Baltimore); 2019 May; 98(19):e15456. PubMed ID: 31083176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    Manoharan A; Shewade DG; Rajkumar RP; Adithan S
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.
    Yin L; Zhang YY; Zhang X; Yu T; He G; Sun XL
    Pharmacopsychiatry; 2015 May; 48(3):95-103. PubMed ID: 25642918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
    Wang HC; Yeh TL; Chang HH; Gean PW; Chi MH; Yang YK; Lu RB; Chen PS
    Psychopharmacology (Berl); 2011 Feb; 213(4):773-9. PubMed ID: 20945066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study.
    Schiele MA; Zwanzger P; Schwarte K; Arolt V; Baune BT; Domschke K
    Int J Neuropsychopharmacol; 2021 Mar; 24(3):191-199. PubMed ID: 33125470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.
    Basu A; Chadda RK; Sood M; Kaur H; Kukreti R
    Indian J Med Res; 2015 Jul; 142(1):40-5. PubMed ID: 26261165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.